Evidence map›Paper›PMID 26703429›Full record

ReviewEuropean journal of internal medicine2016

Uric acid in metabolic syndrome: From an innocent bystander to a central player.

Mehmet Kanbay, Thomas Jensen, Yalcin Solak, Myphuong Le, Carlos Roncal-Jimenez, Chris Rivard, Miguel A Lanaspa, Takahiko Nakagawa, Richard J Johnson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European journal of internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

194 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020
    Trial
  12. Trial
  13. Article
  14. Review
  15. The GPX3-VCAM1 Axis Gates Pro-Fibrotic Tubule Cell Fate in Hyperuricemic Nephropathy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

134 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mehmet KanbayDepartment of Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey. Electronic address: mkanbay@ku.edu.tr.
Thomas JensenDivision of Renal Diseases and Hypertension, University of Colorado, Aurora, CO, USA.
Yalcin SolakDepartment of Medicine, Division of Nephrology, Sakarya Training and Research Hospital, Sakarya, Turkey.
Myphuong LeDivision of Renal Diseases and Hypertension, University of Colorado, Aurora, CO, USA.
Carlos Roncal-JimenezDivision of Renal Diseases and Hypertension, University of Colorado, Aurora, CO, USA.
Chris RivardDivision of Renal Diseases and Hypertension, University of Colorado, Aurora, CO, USA.
Miguel A LanaspaDivision of Renal Diseases and Hypertension, University of Colorado, Aurora, CO, USA.
Takahiko NakagawaTMK Project, Medical Innovation Center, Kyoto University, Kyoto, Japan.
Richard J JohnsonDivision of Renal Diseases and Hypertension, University of Colorado, Aurora, CO, USA; Division of Nephrology, Eastern Colorado Health Care System, Department of Veteran Affairs, Denver, CO, USA.

Funding

PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Edward L Melanson · 1995 to 2026
$32.6M
A novel role for endogenous fructose in ischemic acute kidney injuryK01DK095930 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LANASPA GARCIA, MIGUEL ANGEL · 2012 to 2016
$686k
A novel Role for endogenous fructose production and metabolism in the pathogenesis of contrast-induced nephropathyR03DK105041 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI LANASPA GARCIA, MIGUEL ANGEL · 2015 to 2016
$155k
NIDDK NIH HHS K01 DK095930NIDDK NIH HHS R03 DK105041
6 · The paper itself

Abstract

Uric acid, once viewed as an inert metabolic end-product of purine metabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non-alcoholic fatty liver disease, and chronic kidney disease. Several experimental and clinical studies support a role for uric acid as a contributory causal factor in these conditions. Here we discuss some of the major mechanisms linking uric acid to metabolic and cardiovascular diseases. At this time the key to understanding the importance of uric acid in these diseases will be the conduct of large clinical trials in which the effect of lowering uric acid on hard clinical outcomes is assessed. Elevated uric acid may turn out to be one of the more important remediable risk factors for metabolic and cardiovascular diseases.

Indexed as

Diabetes MellitusHumansHypertensionHyperuricemiaMetabolic SyndromeNon-alcoholic Fatty Liver DiseaseRenal Insufficiency, ChronicRisk FactorsUric AcidUric AcidCardiovascular diseaseDiabetes mellitusHypertensionKidney diseaseMetabolic syndromeUric acid

Identifiers

PMID26703429
PMCPMC4826346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.